1. LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS. (June 2017) Authors: Kolstad, A.; Madsbu, U.; Beasley, M.; Bayne, M.; Illidge, T.; O'Rourke, N.; Lagerlöf, I.; Hájek, R.; Jurczak, W.; Willenbacher, E.; Blakkisrud, J.; Muftuler Løndalen, A.; Rojkjaer, L.; Baylor Curtis, L.; Bloma, M.; Turner, S.; Bolstad, N.; Spetalen, S.; Erlanson, M.; Nygaard, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Open‐label randomized non‐inferiority trial of a fixed‐dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin. Issue 8 (12th December 2015) Authors: Ambery, P.; Stylianou, A.; Atkinson, G.; Dott, C.; Baylor Curtis, L.; Haque, N.; LaCroix, K.; Min, K. W. Journal: Diabetic medicine Issue: Volume 33:Issue 8(2016:Aug.) Page Start: 1084 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗